Carglumic AcidN-氨基甲酰-L-谷氨酸,118

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Carglumic Acid

CAS No. : 1188-38-1

MCE 国际站：Carglumic Acid

产品活性：Carglumic acid (N-Carbamyl-L-glutamic acid) 是 N-乙酰谷氨酸 (NAG) 的功能类似物和氨甲酰磷酸合成酶 1 (CPS1) 的活化剂，用于研究与 N-乙酰谷氨酸合成酶 (NAGS) 缺陷相关的急性和慢性高氨血症。

研究领域：Others

作用靶点：Others

In Vitro: Carglumic acid suppresses cell viability in the pancreatic ductal adenocarcinoma cell lines, triple-negative breast cancer cell lines, hepatoma cell lines, and human non-small cell lung carcinoma cell lines in a dose-dependent manner. The 50% inhibitory concentration (IC₅₀) of Carglumic acid against those cell lines is between 5 and 7.5 mM. The results show that Carglumic acid does not induce complete cell cycle arrest. Instead, there are more sub-G1 cells among Carglumic acid-treated AsPC1 and MDA-MB-231 cells than among untreated cells. In AsPC1 and HPDE-E6E7 cells, the IC₅₀s of Carglumic acid are 5 mM and over 10 mM, respectively . In MDA-MB-231 and MCF-12A cells, the IC₅₀s of Carglumic acid are 5 mM and 6 mM, respectively.

In Vivo: The results show that Carglumic acid, but not the vehicle control, markedly inhibits tumor growth. In the orthotopic pancreatic cancer model, tumor growth inhibition by Carglumic acid on day 21 is 80% (P<0.01). In the orthotopic triple-negative breast cancer model, tumor growth inhibition by Carglumic acid on day 20 is 82% (P<0.01). These results indicate that Carglumic acid suppresses tumor growth in pancreatic cancer and triple-negative breast cancer. On day 20, mean tumor growth inhibition in orally and intravenously treated mice is 55% and 93%, respectively, relative to untreated mice (P<0.01).

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  Peptidomimetic Library  |  Drug Repurposing Compound Library  |  Anti-COVID-19 Compound Library  |  Orally Active Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Anti-Breast Cancer Compound Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Rare Diseases Drug Library  |  EMA-Approved Drug Library  |  FDA-Approved Anticancer Drug Library  |  Human Metabolite Library  |  Off-patent Drug Library  |  Digitonin  |  5-Ph-IAA  |  FLAG peptide  |  Tocofersolan  |  Monocrotaline  |  Lactate sodium  |  TCEP hydrochloride  |  3X FLAG peptide  |  DPPH  |  Pertussis Toxin  |  Pronase E (Activity ≥ 7000 U/g)  |  O-Propargyl-Puromycin  |  NMDI14  |  Phytohemagglutinin  |  MYLS22  |  Hyaluronidase  |  Biotinyl tyramide  |  Kifunensine  |  Human IgG1 kappa, Isotype Control  |  4-Azido-L-phenylalanine  |  6-Aminonicotinamide  |  Ammonium tetrathiomolybdate(VI)  |  OVA Peptide(257-264) TFA  |  Alkyne-phenol  |  Lauryl maltose neopentyl glycol  |  SHIN1  |  CHAPS  |  Cytosporone B

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds